Quinazolinone cholecystokinin (CCK)-B antagonists decrease midbrain dopamine unit activity.
Rasmussen
K
K
Lilly Research Laboratories, Eli Lilly & Co., Lilly Corporate Center, Indianapolis, Indiana 46285.
Yu
M J
MJ
Czachura
J F
JF
D000818:Animals; D002766:Cholecystokinin / Q000037:antagonists & inhibitors*; D004594:Electrophysiology; D007211:Indoles / Q000494:pharmacology; D008297:Male; D008636:Mesencephalon / Q000166:cytology / Q000187:drug effects / Q000502:physiology*; D009474:Neurons / Q000187:drug effects / Q000502:physiology*; D011799:Quinazolines / Q000494:pharmacology; D052999:Quinazolinones; D051381:Rats; D017207:Rats, Sprague-Dawley
D007211:Indoles; D011799:Quinazolines; D052999:Quinazolinones; C090814:LY 247348; C090815:LY 202769; D002766:Cholecystokinin